Scholarlink

<p>Mutations in <i>MYH9</i> and <i>MYH14</i> are associated with autosomal dominant, progressive sensorineural hearing loss. This study aimed to characterize and compare the clinical and audiological features of patients with <i>MYH9</i> or <i>MYH14</i> variants. Thirteen patients with <i>MYH9</i> or <i>MYH14</i> mutations were identified through whole-exome or targeted sequencing and underwent audiometric evaluations. Both groups exhibited late-onset, high-frequency, progressive hearing loss. The <i>MYH9</i> group showed a higher proportion of severe-to-profound cases (41.7%) compared to the <i>MYH14</i> group (14.3%). One <i>MYH14</i> case presented with congenital hearing loss linked to a nonsense variant (p.Q25*), expanding the phenotypic spectrum of <i>MYH14</i>-related hearing loss. Several novel variants were identified in both genes, all of which were extremely rare and predicted to be deleterious by in silico analyses. Contrary to previous reports, no syndromic features were observed in patients with <i>MYH9</i> mutations, although one patient had a marginally elevated mean platelet volume. These findings highlight overlapping auditory phenotypes between <i>MYH9</i> and <i>MYH14</i> mutations, with particularly marked variability in the genetic and phenotypic features in <i>MYH9</i>. Early genetic diagnosis can aid in prognosis and support individualized management for patients with progressive hearing loss caused by variants in non-muscle myosin genes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The audiological phenotype of patients with a variant in MYH9 and MYH14 genes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Seong Hoon Bae,
  • Sun Young Joo,
  • Seung Hyeon Jang,
  • Sung Huhn Kim,
  • Jae Young Choi,
  • Dongju Won,
  • Heon Yung Gee,
  • Jinsei Jung

摘要

Mutations in MYH9 and MYH14 are associated with autosomal dominant, progressive sensorineural hearing loss. This study aimed to characterize and compare the clinical and audiological features of patients with MYH9 or MYH14 variants. Thirteen patients with MYH9 or MYH14 mutations were identified through whole-exome or targeted sequencing and underwent audiometric evaluations. Both groups exhibited late-onset, high-frequency, progressive hearing loss. The MYH9 group showed a higher proportion of severe-to-profound cases (41.7%) compared to the MYH14 group (14.3%). One MYH14 case presented with congenital hearing loss linked to a nonsense variant (p.Q25*), expanding the phenotypic spectrum of MYH14-related hearing loss. Several novel variants were identified in both genes, all of which were extremely rare and predicted to be deleterious by in silico analyses. Contrary to previous reports, no syndromic features were observed in patients with MYH9 mutations, although one patient had a marginally elevated mean platelet volume. These findings highlight overlapping auditory phenotypes between MYH9 and MYH14 mutations, with particularly marked variability in the genetic and phenotypic features in MYH9. Early genetic diagnosis can aid in prognosis and support individualized management for patients with progressive hearing loss caused by variants in non-muscle myosin genes.